Phase 1/2 Study of TG01/QS-21 Vaccine in KRAS/NRAS Mutant High-Risk Smoldering or Active Multiple Myeloma with Measurable Disease Post-Treatment

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **efficacy** of the TG01/QS-21 vaccine in patients diagnosed with high-risk smoldering **multiple myeloma** or multiple myeloma, who have confirmed KRAS or NRAS codon 12/13 mutations and have undergone at least one line of treatment. This investigation is clinically relevant as it aims to address the therapeutic needs of patients with measurable disease, potentially offering a novel treatment option for those with specific genetic mutations associated with multiple myeloma.

The clinical trial involves participants diagnosed with **multiple myeloma**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. Additionally, key inclusion or exclusion criteria have not been disclosed. The selection process for the trial population remains unspecified.

The clinical trial is designed to evaluate the **safety**, tolerability, and efficacy of the TG01/QS-21 vaccine in patients diagnosed with **multiple myeloma** or high-risk smoldering multiple myeloma, who have a confirmed KRAS or NRAS codon 12/13 mutation and evidence of measurable disease after at least one line of treatment. This study is structured as a phase 1/phase 2 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is expected to span approximately 12 years, with an estimated recruitment start date of November 18, 2022, and an anticipated end date of November 18, 2034.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits to monitor their response to the vaccine and any potential adverse effects. These visits will include comprehensive assessments such as physical examinations, laboratory tests, and imaging studies as necessary. The end-of-study visit will occur at the conclusion of the participant's involvement in the trial, where final evaluations will be conducted to gather data on the long-term effects of the treatment.

The expected duration of participant involvement will vary depending on individual response and the progression of the disease, but it is anticipated to last several years. Conditions that may lead to early termination from the study include significant adverse reactions, disease progression that necessitates alternative treatment, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 9, indicating an advanced stage of clinical research. The estimated recruitment start date is November 18, 2022, with an anticipated end date of November 18, 2034. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's effectiveness. The trial's duration and phase suggest a comprehensive approach to evaluating the intervention's impact on the targeted medical condition. The methodology will adhere to rigorous clinical standards to ensure the reliability and validity of the efficacy assessments.